Sirtuin Pipeline

Sirtris is focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases, such as Type 2 Diabetes, and various forms of cancer, as well as mitochondrial, inflammatory, neurodegenerative and cardiovascular diseases.

Pipeline Highlights:

• SRT2104, a new chemical entity (NCE) that activates SIRT1 – structurally unrelated to and up to 1,000 times more potent than resveratrol
  • Currently under way with multiple Phase IIa trials in patients with metabolic disease (Type 2 Diabetes), inflammation and cardiovascular disease
• SRT2379, a potent NCE that activates SIRT1 – structurally distinct from resveratrol and SRT2104
  • Currently being evaluated for safety, tolerability and pharmacokinetics in a Phase I clinical trial
• SRT501, a formulation of resveratrol with roughly five times higher bioavailability than the natural product
  • Completed Phase IIa trial in Type 2 Diabetes (Elliott et al. Drugs Future 2009, 34, 291-295.).
  • Currently under way with a Phase IIa trial in oncology

For further information, please visit clinicaltrials.gov.